SLC5A2 and hydrops fetalis: In the same meta-analysis, when all five studies on SGLT2 inhibitors and HF were incorporated, treatment with an SGLT2 inhibitor resulted in a 23% relative risk reduction in the composite endpoint of CV mortality or HHF.